➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Last Updated: January 17, 2021

DrugPatentWatch Database Preview

Patent: 7,834,016

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,834,016
Title:Inhibitors of the interaction between MDM2 and p53
Abstract: The present invention provides compounds of formula (I), their use as an inhibitor of a p53-MDM2 interaction as well as pharmaceutical compositions comprising said compounds of formula (I) ##STR00001## wherein n, m, p, s, t, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, X, Y, Q and Z have defined meanings.
Inventor(s): Lacrampe; Jean Fernand Armand (Le Mesnil-Esnard, FR), Meyer; Christophe (Les Authieux sur le Port Saint Ouen, FR), Ligny; Yannick Aime Eddy (Sotteville-les-Rouen, FR), Csoka; Imre Christian Francis (Louviers, FR), Van Hijfte; Luc (Belbeuf, FR), Arts; Janine (Breda, NL), Schoentjes; Bruno (Bois-Guillaume, FR), Wermuth; Camille Georges (Strasbourg, FR), Giethlen; Bruno (Altorf, FR), Contreras; Jean-Marie (Benfeld, FR), Joubert; Muriel (Illkirch, FR)
Assignee: Janssen Pharmaceutica NV (Beerse, BE)
Application Number:11/575,552
Patent Claims:see list of patent claims

Details for Patent 7,834,016

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial Janssen Pharmaceutica NV (Beerse, BE) 2024-09-22 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial Janssen Pharmaceutica NV (Beerse, BE) 2024-09-22 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 7,834,016

Country Patent Number Estimated Expiration
South Africa 200702341   Start Trial
World Intellectual Property Organization (WIPO) 2006032631   Start Trial
United States of America 2008039472   Start Trial
United States of America 2011053937   Start Trial
United States of America 8404683   Start Trial
Ukraine 91027   Start Trial
Taiwan 200626579   Start Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.